Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment.
暂无分享,去创建一个
H. Kantarjian | G. Garcia-Manero | J. Cortes | R. Luthra | K. Patel | T. Kadia | F. Ravandi | G. Borthakur | E. Jabbour | N. Short | W. Wierda | A. Ferrajoli | G. Tang | S. Dellasala | K. Sasaki | M. Rios | G. González | G. Issa | G. Gonzalez
[1] S. Gabriel,et al. Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease , 2017, The New England journal of medicine.
[2] R. Sandberg,et al. Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia , 2017, Nature Medicine.
[3] Matthew A. Cooper,et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice , 2017, Science.
[4] Marc S. Tyndel,et al. Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy. , 2017, Blood.
[5] H. Kantarjian,et al. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. , 2016, Blood.
[6] M. Konopleva,et al. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors , 2016, Cancer.
[7] Martin C. Müller,et al. Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML , 2015, Annals of Hematology.
[8] H. Kantarjian,et al. Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. , 2015, The Lancet. Haematology.
[9] H. Kantarjian,et al. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. , 2015, The Lancet. Haematology.
[10] M. McCarthy,et al. Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.
[11] Francisco Cervantes,et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. , 2013, Blood.
[12] L. Shaffer,et al. Cytogenetic Nomenclature: Changes in the ISCN 2013 Compared to the 2009 Edition , 2013, Cytogenetic and Genome Research.
[13] H. Kantarjian,et al. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. , 2013, Blood.
[14] J. Stark,et al. Chronic myelogenous leukemia stem and progenitor cells demonstrate chromosomal instability related to repeated breakage-fusion-bridge cycles mediated by increased nonhomologous end joining. , 2012, Blood.
[15] H. Kantarjian,et al. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy , 2012, Cancer.
[16] Katayoun Rezvani,et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] H. Kantarjian,et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. , 2011, Blood.
[18] A. Nagler,et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. , 2011, Journal of the National Cancer Institute.
[19] Y. Aizawa,et al. Myelodysplastic syndrome with Ph negative monosomy 7 chromosome following transient bone marrow dysplasia during imatinib treatment for chronic myeloid leukemia. , 2011, Internal medicine.
[20] Susan O'Brien,et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Susan O'Brien,et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] J. Radich,et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Martin C. Müller,et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. , 2008, Blood.
[24] M. Baccarani,et al. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome‐negative cells , 2007, Cancer.
[25] D. Colomer,et al. Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia‐positive chronic myeloid leukemia: Two cases with a different outcome , 2007, American journal of hematology.
[26] H. Kantarjian,et al. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. , 2005, Blood.
[27] Francisco Cervantes,et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.
[28] H. Kantarjian,et al. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. , 2006, Blood.
[29] Laurie E Ailles,et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. , 2004, The New England journal of medicine.
[30] H. Kantarjian,et al. Chromosomal abnormalities in Philadelphia chromosome‐negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome‐positive chronic myelogenous leukemia in chronic phase , 2003, Cancer.
[31] H. Kantarjian,et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. , 2003, Blood.
[32] Francisco Cervantes,et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.
[33] Z. Piao,et al. Clinical significance of Y chromosome loss in hematologic disease , 2000, Genes, chromosomes & cancer.
[34] G. Daley,et al. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. , 1990, Science.
[35] J. Rowley. A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining , 1973, Nature.